Home NICO CORPORATION

NICO CORPORATION

    NICO Corporation Expands Internationally

    Over 900 neurosurgeons have attended similar courses in the U.S., Canada and Singapore on Advances in Subcortical Neurosurgery using Minimally Invasive Parafascicular Surgery (MIPS) supported by the BrainPath Approach, NICO's systems approach to addressing both primary and secondary tumors and hemorrhagic stroke -- the deadliest, costliest and most debilitating form of stroke with an annual worldwide incidence rate of 2.1 million.

    NICO Completes $12.5 Million Capital Raise Supported by Current Shareholders

    “Our shareholders have again confirmed their commitment and confidence in the value and outcomes of NICO technologies and our ability to both grow and create new markets in neurosurgery,” said Jim Pearson, president and CEO of NICO Corporation.

    New Technology in Treating Hemorrhagic Stroke: Could Training Lead Toward a New Gold Standard?

    New Technology in Treating Hemorrhagic Stroke Video1: Video 2: Video 3: Video 4: To date, a total of 18 peer-reviewed papers and abstracts that included...

    NICO Launches Investigator Initiated Study Program to Increase Scientific Data Supporting Minimally Invasive Neurosurgery

    NICO has invested more than $8 million in clinical research supporting true minimally invasive neurosurgery approaches using automated technologies for subcortical and skull base procedures.

    NICO Corporation Adds to Strong Intellectual Property Portfolio of 200+ with New Patent Issued Around Revolutionary BrainPath Technology

    Joe Mark, Chief Technology Officer of NICO and primary inventor of its patented technologies comments: “This new issuance further protects the distinctive capabilities of the BrainPath technology and is validation by the patent office that these innovations are relevant and worthy of protecting."

    Early Intervention of Hemorrhagic Stroke Trial Reaches 100 Patients

    6/1/18: “Our goal in funding this important trial is to find an effective treatment for appropriate patients with ICH – the deadliest, costliest and most debilitating form of stroke that currently has no surgical solution,” said Jim Pearson, president and CEO of NICO Corporation.

    New Published Evidence for Deadly High-Grade Gliomas Linked to Improved Survival

    5/22/18: “We have performed extensive studies on extent of resection for high grade gliomas, and all the studies show that increased extent of resection and decreased residual tumor are associated with better survival and delayed recurrence,” said Kaisorn Chaichana, MD, one of the paper’s authors. “However, we have also shown that if you cause a deficit, these patients do worse regardless of your extent of resection.

    NICO Continues to Innovate with Smallest Trans-Sulcal Brain Access Tool in the World

    NICO reports the 11 mm diameter BrainPath® offers smaller footprint and less displacement of brain tissue.

    New Study Reveals Nearly $12,000 per Patient Economic Benefit for Hospitals Using New Technology for Brain Tumor Removal and Stroke Treatment

    HOME A clinically published non-disruptive approach to brain surgery using technologies developed by NICO Corporation has shown a greater than 50 percent...

    New Technology in Treating Hemorrhagic Stroke: Could Training Lead Toward a New Gold Standard?

    Could Training Lead Toward a New Gold Standard? To date, a total of 18 peer-reviewed papers and abstracts that included 221 cases have been published...

    NICO Announces CE Mark for BrainPath® Non-Disruptive Cranial Access Technology

    “This new way to do brain surgery has a growing body of peer-reviewed evidence of improved patient outcomes for both tumor removal and hemorrhagic stroke,” he added. “We’re very excited to be the first in the UK to offer this technology.”

    RECENT COMMENTS